Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: LL-37 evidence and protocol review
Also known as: Cathelicidin LL-37
LL-37 is the C-terminal fragment of the only human cathelicidin identified to date, hCAP-18, expressed mainly by neutrophils and epithelial cells. Beyond its broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses, LL-37 has documented cellular activities including chemotaxis, epithelial cell activation, angiogenesis, and epithelial wound repair, alongside cytotoxicity to host cells and roles in inflammatory signaling (including RNA presentation to scavenger receptors) that can be double-edged in chronic inflammatory skin conditions like rosacea.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
No published SC human protocol supports the four duplicate schedules. Lower topical concentrations showed the trial signal while 3.2 mg/mL did not; cytotoxicity, proteolysis, and context-dependent tumor biology remain development concerns.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.